Received Mar 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | 2 | AE2J7 | — |
second dose recently on March Twenty-twenty five; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 11-year-old female patient who received Flu Seasonal TIV Quebec (FluLaval 2024-2025 season) (batch number AE2J7, expiry date 16-AUG-2025) for prophylaxis. On 07-MAR-2025, the patient received the 2nd dose of FluLaval 2024-2025 season. On an unknown date, an unknown time after receiving FluLaval 2024-2025 season, the patient experienced extra dose administered (Verbatim: second dose recently on March Twenty-twenty five). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 10-MAR-2025 The reporter reported that a patient that was administered a first dose of Flulaval in September 2024 and a second dose recently in March 2025, which led to extra dose administered.